<?xml version="1.0" encoding="UTF-8"?>
<p>Cystatin-C, a small endogenous polypeptide, that physiologically acts as a cysteine protease inhibitor and is used as a biomarker of kidney [
 <xref rid="B84-ijms-21-03492" ref-type="bibr">84</xref>] or brain [
 <xref rid="B85-ijms-21-03492" ref-type="bibr">85</xref>] injury, has antiviral properties [
 <xref rid="B86-ijms-21-03492" ref-type="bibr">86</xref>,
 <xref rid="B87-ijms-21-03492" ref-type="bibr">87</xref>,
 <xref rid="B88-ijms-21-03492" ref-type="bibr">88</xref>] and was found to be reduced in Vero E6 cells infected with a porcine epidemic diarrhea coronavirus [
 <xref rid="B89-ijms-21-03492" ref-type="bibr">89</xref>]. Furthermore, it has been used at slightly supraphysiological levels in a previous study to reduce viral titers of two human coronaviruses in cell cultures, where the authors hypothesized a PLP as target, [
 <xref rid="B79-ijms-21-03492" ref-type="bibr">79</xref>] and internalization of Cystatin C in cells has been demonstrated [
 <xref rid="B90-ijms-21-03492" ref-type="bibr">90</xref>]. On the basis of these considerations, we would propose further studies on cystatin C antiviral properties against highly pathogenic coronaviruses. i.e., investigate the outcome of COVID-19 in patients with high levels of cystatin C.
</p>
